Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"GLP-1 receptor agonists"”.
-
Understanding Patient Perceptions and Behavioral Intentions Toward GLP-1 Receptor Agonists for Weight Management in the United States: A Health Belief Model Approach
<p>Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for weight management in the United States; however, limited evidence exists regarding the perceptual and behavioral factors influencing medication adherence among adult users. Prior research has largely …
-
The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on cell viability, ADAM10 maturation and the proteolysis of ADAM10 substrates in SH-SY5Y cells
… has suggested that glucagon-like peptide-1 (GLP-1) analogues; Lixisenatide, Dulaglutide, Liraglutide, and Exenatide (Exendin-4), currently used to treat diabetes, may also be beneficial in the treatment of neurodegenerative conditions such as AD, as they have been shown to exert …
-
Cardiovascular Effects of GLP-1 and Glucagon Dual Receptor Agonism in Humans
… IV inhibitors, glucagon like peptide-1 (GLP-1) receptor agonists and selective sodium-glucose transporter-2 inhibitors (SGLT2i). These medications have transformed treatment pathways and prognosis for individuals with T2DM as well as obesity (GLP-1 receptor agonists), heart failure …
-
Central mechanisms underlying the synergistic anorectic effect of CCK and GLP-1 combination therapy
… (CCK) and Glucagon-like peptide-1 (GLP-1) are gut hormones produced in response to meal ingestion that promote satiety and meal termination. Co-infusion of long-acting CCK and GLP-1 receptor agonists have been shown to synergistically reduce food intake and body-weight in …
-
Effect of Semaglutide on Vascular Regenerative Cells in People at Elevated Risk for Atherosclerosis
… trials demonstrated that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment can reduce major adverse cardiovascular events (MACE) in people with type 2 diabetes (T2D) and/or obesity. However, the mechanisms of vascular benefit remain unknown. In particular, the mechanisms of semaglutide, …